Clinical Trials

Sponsor: Atara Biotherapeutics, Inc.

Sponsor Study ID: ATA129-EBV-302

Study Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein Barr Virus Associated Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)

NCT Number: NCT03394365

Phase: III

Protocol Type: Treatment

Age Group: Both

Disease Sites: Kidney, Liver, Lung, Pancreas, Small Intestine

Study Objectives: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)

---

Study Documents    
(MUSC NetID required for document access)